Fungiter 5 % medicated nail lacquer Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

fungiter 5 % medicated nail lacquer

5 % medicated nail lacquer

Exoterin 78,22 mg/ml medicated nail lacguer Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

exoterin 78,22 mg/ml medicated nail lacguer

78,22 mg/ml medicated nail lacguer

Voltaren 140 mg medicated plaster Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

voltaren 140 mg medicated plaster

140 mg medicated plaster

Simvastatin Medica 10 mg film - coated tablets Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

simvastatin medica 10 mg film - coated tablets

Медика АД - Симвастатин - 10 mg film - coated tablets

Simvastatin Medica 20 mg film - coated tablets Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

simvastatin medica 20 mg film - coated tablets

Медика АД - Симвастатин - 20 mg film - coated tablets

Simvastatin Medica 40 mg film - coated tablets  Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

simvastatin medica 40 mg film - coated tablets 

Медика АД - Симвастатин - 40 mg film - coated tablets 

Sotyktu Unión Europea - búlgaro - EMA (European Medicines Agency)

sotyktu

bristol-myers squibb pharma eeig - deucravacitinib - псориазис - Имуносупресори - treatment of moderate-to-severe plaque psoriasis in adults.

Opdualag Unión Europea - búlgaro - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - Меланомът - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Pepaxti Unión Europea - búlgaro - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - Множествена миелома - Антинеопластични средства - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Firmagon Unión Europea - búlgaro - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - дегареликс - Простатни неоплазми - Ендокринна терапия - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.